Xcell Biosciences, Royal Perth Hospital Collaboration Announcement

Congratulations to portfolio company, Xcell Biosciences, for their collaboration with The Royal Perth Hospital to develop an automated, clinical-scale manufacturing workflow for therapies based on tumor-infiltrating lymphocytes (TILs) using the AVATAR™ Foundry system.  TIL therapies are a promising type of cellular immunotherapy used to treat a broad range of solid malignant tumors but require tens of billions of therapeutic cells to achieve sufficient clinical potency.  To address these challenges, Xcellbio has developed the AVATAR platform to expedite the development and manufacture of potent cell therapies.